Jay Feingold - Mar 24, 2023 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Role
Chief Medical Officer
Signature
/s/ Pamela Connealy, Attorney-in-Fact for Jay Feingold
Stock symbol
PYXS
Transactions as of
Mar 24, 2023
Transactions value $
$0
Form type
4
Date filed
3/28/2023, 04:45 PM
Previous filing
Jan 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction PYXS Common Stock Award $0 +210K +40.3% $0.00 730K Mar 24, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PYXS Stock Option (Right to buy) Disposed to Issuer -157K -100% 0 Mar 24, 2023 Common Stock 157K $8.71 Direct F2, F3
transaction PYXS Stock Option (Right to buy) Disposed to Issuer -17.5K -100% 0 Mar 24, 2023 Common Stock 17.5K $8.71 Direct F2, F4
transaction PYXS Stock Option (Right to buy) Award +157K 157K Mar 24, 2023 Common Stock 157K $2.21 Direct F2, F3
transaction PYXS Stock Option (Right to buy) Award +17.5K 17.5K Mar 24, 2023 Common Stock 17.5K $2.21 Direct F2, F4

Explanation of Responses:

Id Content
F1 Represents restricted stock units that vest 25% on March 24, 2024, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
F2 In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.
F3 These stock options vested 25% on the first anniversary of the September 13, 2021 grant date, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
F4 These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.